Generalized Pustular Psoriasis: A Consensus Statement from the National Psoriasis Foundation

By sjmartinez • October 15, 2023

Armstrong AW, Elston CA, Elewski BE, Ferris LK, Gottlieb AB, Lebwohl MG; Medical Board of the National Psoriasis Foundation.. Generalized Pustular Psoriasis: A Consensus Statement from the National Psoriasis Foundation. J Am Acad Dermatol. 2023 Oct 12:S0190-9622(23)02969-9. doi: 10.1016/j.jaad.2023.09.080. Epub ahead of print. PMID: 37838256.

Tags: access, consensus statement, Dermatology, generalized pustular psoriasis, IL-36 inhibition, imsidolimab, national psoriasis foundation, psoriasis, Publications, spesolimab, therapy, Treatment

Evaluating the Role of Dermatologic Continuity and Determinants of Psychiatric Engagement in Delusional Infestation: A Single-Institution Cross-Sectional Study

Yan MJ, Poppens MJ, Longstaff XR, Collier EK, Davis JC. Evaluating the Role of Dermatologic Continuity and Determinants of Psychiatric Engagement in Delusional Infestation: A[...]

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension

Augustin M, Feldman SR, Warren RB, Armstrong A, Vender R, López-Ferrer A, Dawe WH, Lambert J, Szilagyi B, Hoepken B, Warham R, Gottlieb AB. Three-Year[...]

The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trial

Silverberg JI, Eichenfield LF, Armstrong AW, Bagel J, Lockshin B, Boh E, Koo J, Farberg AS, Goldberg MS, Quick AP, Lebwohl MG. The 487-gene expression[...]